• Sign In
  • FAQ
  • Create an Account
  • 866-930-6790
Currency
USD
Toggle Nav
My Cart
Search
Menu
Account
Settings
Currency
USD

PDGFR

Items 1-50 of 69

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. A10001
    Sorafenib Tosylate (Nexavar)

    Raf inhibitor

    Sorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
    Quick View
  2. A10025
    Linifanib (ABT-869)

    VEGFR/PDGFR inhibitor

    Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.

    Quick View
  3. A10080
    AP24534 (Ponatinib)

    BCR-ABL inhibitor

    AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor.
    Quick View
  4. A10101
    Tivozanib (AV-951)

    VEGFR Inhibitor

    Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
    Quick View
  5. A10103
    Axitinib

    VEGFR inhibitor

    Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
    Quick View
  6. A10137
    Bibf1120 (Nintedanib)

    VEGFR inhibitor

    BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.
    Quick View
  7. A10198
    Dovitinib Dilactic acid (TKI258 Dilactic acid)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  8. A10250
    Regorafenib (BAY 73-4506)

    VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
    Quick View
  9. A10259
    Imatinib (Gleevec)

    PDGFR inhibitor

    Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.
    Quick View
  10. A10468
    Imatinib Mesylate

    Bcr-Abl inhibitor

    Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway.
    Quick View
  11. A10502
    Ki8751

    VEGFR-2 inhibitor

    Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays.
    Quick View
  12. A10504
    KRN 633

    VEGFR Inhibitor

    KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ??? 10 μM).
    Quick View
  13. A10558
    Masitinib ( AB1010)

    c-Kit inhibitor

    Masitinib (AB1010) is a protein tyrosine kinase inhibitor.
    Quick View
  14. A10608
    Motesanib Diphosphate (AMG-706)

    VEGFR inhibitor

    Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.
    Quick View
  15. A10610
    MP470 (MP-470, Amuvatinib)

    RTK inhibitor

    MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.
    Quick View
  16. A10699
    Pazopanib HCl (GW786034)

    VEGFR/PDGFR/FGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  17. A10880
    Sunitinib Malate

    RTK inhibitor

    Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
    Quick View
  18. A10903
    Telatinib (BAY 57-9352)

    VEGFR-2 inhibitor

    Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.
    Quick View
  19. A10953
    TSU-68 (Orantinib, SU6668)

    PDFGRβ inhibitor

    Orantinib (TSU-68, SU6668) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.
    Quick View
  20. A11052
    Crenolanib (CP-868596)

    PDGFR/FLT3 Inhibitor

    Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.
    Quick View
  21. A11207
    PP121

    PI3K Inhibitor

    PP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR).
    Quick View
  22. A11350
    CP-673451

    PDGFRα/β inhibitor

    CP 673451 is a potent PDGFR-β inhibitor with an IC50 of 1 nM.
    Quick View
  23. A11472
    Ki 20227

    M-CSFR, CSF1R inhibitor

    Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R).
    Quick View
  24. A11518
    Pazopanib (GW-786034)

    VEGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  25. A11546
    Regorafenib Hydrochloride

    VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Quick View
  26. A11556
    SU14813 maleate

    multi-targeted receptor tyrosine kinases inhibitor

    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
    Quick View
  27. A11581
    Toceranib (PHA 291639, SU 11654)

    c-Kit, PDGFR, VEGFR inhibitor

    Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
    Quick View
  28. A11753
    MK-2461

    c-Met Inhibitor

    MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Quick View
  29. A12005
    Sorafenib N-Oxide

    Raf kinase inhibitor

    Sorafenib N-Oxide is a metabolite of Sorafenib, a potent Raf kinase inhibitor.
    Quick View
  30. A12486
    Tyrosine kinase-IN-1

    multi-targeted tyrosine kinase inhibitor

    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.
    Quick View
  31. A13111
    R1530

    Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor

    R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
    Quick View
  32. A13530
    Flumatinib mesylate

    c-Abl/c-Kit/PDGRFβ inhibitor

    Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
    Quick View
  33. A13545
    JI-101

    VEGFR2/PDGFRβ/EphB4 inhibitor

    JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities.
    Quick View
  34. A13555
    TAK-593

    VEGFR/PDGFR inhibitor

    TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity.
    Quick View
  35. A14156
    AZD 2932

    mutil-targeted protein tyrosine kinase inhibitor

    AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
    Quick View
  36. A15062
    DCC-2618

    C-Kit/PDGFR inhibitor

    DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively.
    Quick View
  37. A15152
    Masitinib mesylate

    KIT/PDGFR inhibitor

    Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
    Quick View
  38. A15182
    N-Desethyl Sunitinib

    VEGFR/PDGFRβ/KIT inhibitor

    N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively).
    Quick View
  39. A15218
    Regorafenib monohydrate

    Tyrosine kinase inhibitor

    Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
    Quick View
  40. A15263
    Toceranib phosphate

    c-Kit/VEGFR2/PDGFRβ inhibitor

    Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
    Quick View
  41. A15933
    AC710

    FLT3/KIT/PDGFRα/PDGFRβ inhibitor

    AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.
    Quick View
  42. A16197
    Nintedanib esylate

    RTK inhibitor

    Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
    Quick View
  43. A16246
    AC710 Mesylate

    FLT3/KIT/PDGFRα/PDGFRβ inhibitor

    AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
    Quick View
  44. A16258
    Flumatinib

    multi-kinase inhibitor

    Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively.
    Quick View
  45. A16773
    Tyrphostin AG1296

    PDGFR inhibitor

    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM.
    Quick View
  46. A17039
    Ningetinib Tosylate

    VEGF and PDGF inhibitor

    Ningetinib Tosylate,also known as CT-053Tosylate and DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration. CAS: 1394820-69-9 (free base) 1394820-77-9 (tosylate)
    Quick View
  47. A17076
    Anlotinib HCl

    RTK inhibitor

    Anlotinib, also known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. CAS: 1058156-90-3 (free base) 1360460-82-7 (HCl)
    Quick View
  48. A17227
    AG1295

    PDGFR inhibitor

    AG1295 is a PDGF receptor specific inhibitor.
    Quick View
  49. A17409
    Trapidil

    Trapidil is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor.
    Quick View
  50. A17567
    Lenvatinib mesylate

    multi-targeted tyrosine kinase inhibitor

    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Quick View

Items 1-50 of 69

Page
per page
Set Descending Direction